Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation

Oncotarget. 2018 Sep 25;9(75):34190. doi: 10.18632/oncotarget.26197.

Inik Chang¹, Yozo Mitsui^{2

3}, Seul Ki Kim^{1

4}, Ji Su Sun^{1

4}, Hye Sook Jeon¹, Jung Yun Kang^{1

4}, Nam Ju Kang^{1

4}, Shinichiro Fukuhara^{2

3}, Ankurpreet Gill², Varahram Shahryari², Z Laura Tabatabai⁵, Kirsten L Greene⁵, Rajvir Dahiya^{2

3}, Dong Min Shin^{1

4}, Yuichiro Tanaka^{2

3}

¹ Department of Oral Biology, Yonsei University College of Dentistry, Seoul, South Korea.
² Department of Surgery and Division of Urology, Veterans Affairs Medical Center, San Francisco, California, United States of America.
³ Department of Urology, University of California, San Francisco, California, United States of America.
⁴ BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, South Korea.
⁵ Department of Pathology, Veterans Affairs Medical Center and University of California, San Francisco, California, United States of America.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.16598.].